{"id":7826,"date":"2025-10-23T23:02:57","date_gmt":"2025-10-23T23:02:57","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/10\/23\/fda-approves-blenrep-gsk-drug-multiple-myeloma\/"},"modified":"2025-10-23T23:02:57","modified_gmt":"2025-10-23T23:02:57","slug":"fda-approves-blenrep-gsk-drug-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/10\/23\/fda-approves-blenrep-gsk-drug-multiple-myeloma\/","title":{"rendered":"STAT+: FDA delivers split decision on GSK\u2019s blood cancer drug Blenrep, approving its use in some cases"},"content":{"rendered":"<p>    STAT+: FDA delivers split decision on GSK\u2019s blood cancer drug Blenrep, approving its use in some cases<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in one combination regimen but rejecting another.\u00a0<\/p>\n<p>The mixed ruling is the latest twist in the turbulent history of the multiple myeloma drug, called Blenrep.\u00a0<\/p>\n<p>GSK had submitted different Blenrep combinations to the FDA as treatments for patients with the disease who had already tried at least one other therapy, with one regimen being tested in the <a href=\"https:\/\/www.statnews.com\/2024\/12\/09\/ash-2024-gsk-myeloma-blenrep-improves-survival-in-trial\/\">DREAMM-7<\/a> trial and the other in the <a href=\"https:\/\/www.statnews.com\/2024\/06\/02\/multiple-myeloma-blenrep-gsk-asco\/\">DREAMM-8<\/a> study. Both studies showed Blenrep helped cut the risk of disease progression or death, and DREAMM-7 also demonstrated a benefit on overall survival.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/10\/23\/fda-approves-blenrep-gsk-drug-multiple-myeloma\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Andrew Joseph<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/10\/23\/fda-approves-blenrep-gsk-drug-multiple-myeloma\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: FDA delivers split decision on GSK\u2019s blood cancer drug Blenrep, approving its use in some cases The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in one combination regimen but rejecting another.\u00a0 The mixed ruling is the latest twist in the turbulent [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2208,2155,2152],"tags":[2150],"class_list":["post-7826","post","type-post","status-publish","format-standard","hentry","category-biotech","category-drug-development","category-pharmaceuticals","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7826"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=7826"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/7826\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=7826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=7826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=7826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}